Safusidenib could eclipse the recently approved brain cancer drug, Nuvation claims.

Servier's vorasidenib had shown promise at ASCO, but Lilly's dual IDH project LY3410738 leaves the pipeline.

Toxicity casts a shadow over vorasidenib’s prospects as possibly the first targeted therapy for low-grade glioma.